Streetbeat News

Stock Prices

VNDA

Vanda Pharmaceuticals (NASDAQ:VNDA) reported Q2 2024 GAAP EPS of $(0.08), beating the estimate of $(0.21) by 61.9%. Sales were $50.474M, surpassing the $47.860M estimate and showing a 9.59% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:28 pm

CCRN

Cross Country Healthcare has provided guidance for Q3 2024 adjusted EPS in the range of $0.08 to $0.12, which is below the analyst estimate of $0.13.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:27 pm

ACLS

Axcelis Technologies (NASDAQ:ACLS) reported Q2 2024 GAAP EPS of $1.55, beating the estimate of $1.35. Sales were $256.512M, surpassing the $250.302M estimate. Despite the beats, sales decreased by 6.37% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:26 pm

EVTC

Evertec has provided its financial guidance for FY24, projecting revenue between $846M and $854M, which is in line with the market estimate of $850.49M. The company also expects adjusted EPS to be in the range of $2.98 to $3.07, surpassing the market estimate of $2.90.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:26 pm

CCRN

Cross Country Healthcare (NASDAQ:CCRN) reported Q2 2024 earnings per share of $0.10, missing the analyst estimate of $0.13 by 23.08%. However, the company reported sales of $339.77 million, beating the estimate of $334.76 million by 1.50%. This represents a 37.16% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:26 pm

GKOS

Glaukos Corporation has provided its revenue guidance for FY24, expecting net sales to be in the range of $370 million to $376 million, surpassing the estimated $363.02 million.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:26 pm

FICO

FICO has updated its fiscal year 2024 guidance, projecting revenues between $1.69 billion and $1.7 billion, slightly below the $1.707 billion estimate. The company also sees adjusted EPS between $22.80 and $23.16, compared to the $23.63 estimate.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:25 pm

EVTC

Evertec (NYSE: EVTC) reported Q2 2024 adjusted EPS of $0.83, beating the $0.69 estimate by 20.29%. Sales were $212 million, surpassing the $211.103 million estimate and marking a 26.89% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:25 pm

ALB

Albemarle maintains its full-year outlook but reduces its Specialties adjusted EBITDA outlook due to slower market rebound and higher logistics costs from the Middle East conflict. The company expects a charge of $0.9-$1.1 billion in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:25 pm

TMDX

TransMedics Group has raised its full-year 2024 revenue guidance from $390M-$400M to $425M-$445M, significantly above the previous estimate of $401.43M. This new guidance represents a 76% to 84% growth compared to the prior year's revenue.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 8:25 pm